- Home
- KOYN vs ZNTL Comparison
KOYN vs ZNTL Comparison
Compare KOYN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.09
Company Overview
Basic Information| Metric | KOYN | ZNTL |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.5M | 289.0M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KOYN | ZNTL |
|---|---|---|
| Price | $10.23 | $3.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 46.0K | ★ 799.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.85 | $1.21 |
| 52 Week High | $10.25 | $6.95 |
Technical Indicators
Market Signals| Indicator | KOYN | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 30.92 |
| Support Level | $10.08 | $2.09 |
| Resistance Level | $10.25 | $3.30 |
| Average True Range (ATR) | 0.01 | 0.22 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 40.00 | 13.39 |
Price Performance
Historical Comparison KOYN
ZNTL
About KOYN CSLM Digital Asset Acquisition Corp III Class A Ordinary Shares
CSLM Digital Asset Acquisition Corp III Ltd is a blank check company that acts to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.